Skip to main content
Nancy Lin on Muck Rack

Nancy Lin

Boston
As seen in: Nature, Wiley Online Library, Memory Studies, Oxford Academic, The Oncologist, MDPI, SAGE Publishing, JAMA Network, JAMA Oncology, Medscape and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Nancy

Contact Nancy, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Clinical responses to trastuzumab deruxtecan in molecularly defined ependymoma

|
By L. Castro, Yi-Chien Wu, Jia-Ren Lin, Maria-Joao Santiago-Ribeiro, Alice Laurenge, Alexandre Carpentier, Shannon Coy, Nancy Lin, Keith L. Ligon, Mehdi Touat, Sandro Santagata, Karima Mokhtari
| Nature Verified
Abstract Despite evidence that antibody drug conjugates (ADCs) are active in brain metastases, their role in primary central nervous system (CNS) tumors remains unclear. We report two adults with molecularly defined ependymoma – a MYCN-amplified spinal tumor with intracranial dissemination and a supratentorial ZFTA-RELA-fused tumor with multiple recurrences – who demonstrated radiographic response and/or durable clinical and metabolic stability with trastuzumab deruxtecan (T-DXd).
Open in Who Shared Issue with article?

Circulating Tumor DNA in Early Breast Cancer : A Review

|
By Ilana Schlam, Sara M. Tolaney, Nancy Lin, Heather A. Parsons, Stefania Morganti
| JAMA Oncology Verified
Abstract Importance Circulating tumor DNA (ctDNA) has emerged as a noninvasive biomarker with the potential to detect minimal residual disease (MRD), monitor treatment response, and identify recurrence (eg, molecular relapse) earlier than conventional clinical or imaging approaches. Although ctDNA-based MRD assays have demonstrated prognostic value in early breast cancer, their optimal clinical utility remains uncertain.
Open in Who Shared Issue with article?

Carboplatin with or without nivolumab in metastatic triple-negative breast cancer: a randomized phase II trial

|
By Ana C. Garrido-Castro, Noah Graham, Katelyn X. Li, Jett Crowdis, Kevin Bi, Jihye Park, Ricardo Garcia Pastorello, Yvonne Y. Li, Hersh V. Gupta, Thomas Kuntz, Russell Petry, Lincoln W. Pasquina, Ashka Patel, Molly DiLullo, Anna Frey, Merrida A Childress, Robert Wesolowski, Natalie Sinclair, Sarah Sinclair, Steve Lo, Nadine Tung, Peter Kaufman, Caroline Block, Wendy S. Chen, Kai W. Wucherpfennig, Ye Tian, Amy Williams Verified, Satabhisa Mukhopadhyay, Tathagata Dasgupta, Stuart J. Schnitt, Andrew D. Cherniack, Jennifer A. Ligibel, Nancy Lin, Elizabeth A. Mittendorf, Nabihah Tayob, Eliezer Van Allen, Sara M. Tolaney, Lynn Bi, Paulina Lange, Victoria Attaya, Meredith Faggen, Jeanna Walsh, Madhavi Toke, Romualdo Barroso
| Nature Verified
Abstract This multi-institutional randomized phase II clinical trial (NCT03414684) investigated the efficacy and safety of carboplatin plus nivolumab compared to carboplatin in metastatic triple-negative breast cancer (mTNBC). The primary endpoint was progression-free survival (PFS) in a modified intention-to-treat (mITT) population of patients with chemotherapy-naïve (i.e., first-line) mTNBC.
Open in Who Shared Issue with article?
See all 157 licensed articles (184 Total)